A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Phase of Trial: Phase II/III
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.
- 27 Nov 2018 Planned initiation date changed from 14 Nov 2018 to 12 Feb 2019.
- 03 Aug 2018 New trial record